Oncolytics Biotech (ONCY) Accumulated Expenses (2024 - 2025)
Oncolytics Biotech's (ONCY) quarterly Accumulated Expenses came in at $2.3 million in Q4 2025, down 9.6% year-on-year from $2.6 million in Q4 2024, and down 9.6% on a QoQ basis from $2.6 million in Q4 2024.
Oncolytics Biotech (ONCY) Accumulated Expenses (2024 - 2025) Analysis & Trends
Oncolytics Biotech (ONCY) has 2 years of Accumulated Expenses data on file, last reported at $2.3 million in Q4 2025.
- On a quarterly basis, Accumulated Expenses fell 9.6% year-over-year to $2.3 million in Q4 2025; TTM through Dec 2025 was $2.3 million, a 9.6% decrease from a year earlier, with the FY2025 full-year figure at $2.3 million, down 9.6% from the prior year.
- Accumulated Expenses for Q4 2025 stood at $2.3 million, down from $2.6 million in the prior quarter.
- Over the last five years, Accumulated Expenses for ONCY reached as high as $2.6 million in Q4 2024 and fell as low as $2.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Oncolytics Biotech | 372.40 Mn | 372.40 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.33 Mn |
| Dec 31, 2024 | 2.57 Mn |